As reflected in the other treatment areas, 2016 appears – but to be confirmed in future - to be a low point in the cycle for clinical research, and this includes trials for treatments related to diseases of the nervous system. The UK and Germany are competitive to be leading sites for research globally, apart from the US. However, the movement in the number of trials across the years is broadly similar across countries, reflecting an underlying pattern in the research programmes globally. Overall, the number of trials reported was fewer than for oncology, but more than for cardiovascular and metabolic disease.
Data was collected from Cortellis Clinical Trial Intelligence, Clarivate Analytics using the following criteria: trial start date (1st January 2012 – 31st December 2016), phase (I, II, III), and country (UK, Spain, Germany, France, Italy, Poland, USA, Canada, Australia, and Japan). Only trials related to pharmaceutical drug development and molecular/biological entities were included. Only commercial trials were included. Collaborative trials were only included if one or more partners were a commercial organisation. All therapeutic areas were included in this analysis. This analysis focused on central nervous treatment trials only. Trials across multiple therapy areas were only included once. The therapy area in which they were included was determined by the trial’s main purpose for study.